Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.